瘤内维地莫德联合 PD-1 阻断剂治疗局部晚期黑色素瘤。
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma.
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
出版信息
Cancer Cell. 2024 Nov 11;42(11):1813-1814. doi: 10.1016/j.ccell.2024.10.001. Epub 2024 Oct 31.
Combinatorial immunotherapy may improve the efficacy of neoadjuvant checkpoint inhibitors in locoregionally advanced melanoma. In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial of the TLR9 agonist vidutolimod in combination with nivolumab. Analyses suggest a unique myeloid expression signature is associated with response.
联合免疫疗法可能提高新辅助检查点抑制剂治疗局部晚期黑色素瘤的疗效。在本期 Cancer Cell 杂志上，Davar 及其同事报告了一项很有前景的 TLR9 激动剂 vidutolimod 联合 nivolumab 的新辅助 2 期临床试验。分析表明，一种独特的髓系表达特征与治疗反应相关。
Zotero 插件